Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040943 | 0.84 | CRBN (0.69) | LMNAMAPTKMT2AMEN1ALOX5 | |
| SCHEMBL2536247 | 0.79 | DDB1 (0.72) | MAPTKMT2AMEN1ALOX5DDB1 | |
| SCHEMBL11500229 | 0.79 | KMT2A (0.39) | LMNAMAPTKMT2AMEN1ALOX5 | |
| SCHEMBL7555132 | 0.76 | DDB1 (0.45) | LMNAMAPTKMT2AMEN1DDB1 | |
| SCHEMBL11097554 | 0.76 | MGLL (0.46) | LMNAMAPTKMT2AMEN1DDB1 | |
| SCHEMBL8632730 | 0.76 | ALOX5 (0.50) | MAPTKMT2AMEN1ALOX5DDB1 | |
| SCHEMBL8631856 | 0.76 | KMT2A (0.66) | LMNAKMT2AMEN1DDB1CRBN | |
| SCHEMBL8575697 | 0.75 | NOTUM (0.44) | LMNAMAPTKMT2AMEN1CASP1 | |
| SCHEMBL6032492 | 0.75 | KMT2A (0.38) | LMNAMAPTKMT2AMEN1DDB1 | |
| SCHEMBL2006546 | 0.74 | ALDH1A1 (0.41) | LMNAMAPTKMT2AMEN1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12429483-B2 | System and method for determining onset and disease progression | RESPIRATION SCAN LTD (IL) | 2025-09-30 | — | — | US | claimed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12429483-B2 | System and method for determining onset and disease progression | RESPIRATION SCAN LTD (IL) | 2025-09-30 | — | — | US | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4164481-B1 | A DEVICE FOR MEASURING VOLATILE MARKERS IN BREATH | NANOSE MEDICAL LTD (IL) | 2024-10-16 | — | — | EP | disclosed |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230337934-A1 | A DEVICE FOR MEASURING VOLATILE MARKERS IN BREATH | NANOSE MEDICAL LTD (IL) | 2023-10-26 | — | — | US | disclosed |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-4164481-A1 | A DEVICE FOR MEASURING VOLATILE MARKERS IN BREATH | Nanose Medical Ltd (IL) | 2023-04-19 | — | — | EP | disclosed |
| US-20220317122-A1 | SYSTEM AND METHOD FOR DETERMINING ONSET AND DISEASE PROGRESSION | RESPIRATION SCAN LTD. (IL) | 2022-10-06 | — | — | US | disclosed |
| WO-2021250674-A1 | A DEVICE FOR MEASURING VOLATILE MARKERS IN BREATH | NANOSE MEDICAL LTD (IL) | 2021-12-16 | — | — | WO | disclosed |
| US-11110100-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210186987-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021028928-A1 | SYSTEM AND METHOD FOR DETERMINING ONSET AND DISEASE PROGRESSION | RESPIRATION SCAN LTD (IL) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021026124-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20110171308-A1 | PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL PREPARATION AND PREPARATION METHOD THEREOF | BEIJING UNIVERSITY (CN) | 2011-07-14 | — | — | US | disclosed |
| EP-2236130-A1 | PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL FORMULATION AND PREPARATION METHOD THEREOF | Beijing University (CN) | 2010-10-06 | — | — | EP | disclosed |
| US-7597804-B2 | Optically active support materials, their method of preparation and their uses | EKA CHEMICALS (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20050209100-A1 | Optically active support materials, their method of preparation and their uses | EKA CHEMICALS (SE) | 2005-09-22 | — | — | US | disclosed |
| CN-1617762-A | Optically active support material, method for the production thereof and use thereof | EKA CHEMICALS AB (SE) | 2005-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | LMNA 3480/4885MAPT 2080/4885KMT2A 2155/4885 |
| US-20210186987-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | LMNA 3480/4885MAPT 2080/4885KMT2A 2155/4885 |
| US-11110100-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | LMNA 3480/4885MAPT 2080/4885KMT2A 2155/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | LMNA 2794/4885MAPT 809/4885KMT2A 3151/4885 |
| US-11679117-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | LMNA 3480/4885MAPT 2080/4885KMT2A 2155/4885 |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | LMNA 3480/4885MAPT 2080/4885KMT2A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.